Comparative Pharmacology
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIALYTE LM DEXTROSE 2 5 IN PLASTIC CONTAINER versus DIALYTE LM DEXTROSE 4 25 IN PLASTIC CONTAINER.
DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER vs DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dialysis solution containing dextrose and electrolytes; dextrose provides osmotic gradient for ultrafiltration and caloric supplementation, while electrolytes maintain acid-base and electrolyte balance in peritoneal dialysis.
Removes waste products (e.g., urea, creatinine) and excess electrolytes via diffusion and ultrafiltration across the peritoneal membrane; dextrose acts as osmotic agent to generate ultrafiltration.
Intravenous infusion, 500-2000 mL per day as maintenance fluid; rate adjusted based on clinical status, typically 1-2 mL/kg/hour in adults.
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges daily, as part of continuous ambulatory peritoneal dialysis (CAPD).
None Documented
None Documented
Terminal half-life: 2.5–3.5 hours. Clinically, this allows for rapid clearance; accumulation may occur in renal impairment.
Not applicable; dextrose is rapidly metabolized (half-life ~2-5 min), electrolytes are distributed and excreted renally with half-life dependent on renal function.
Renal: >95% as unchanged drug and metabolites. Biliary/fecal: <5%.
Renal: 100% (electrolytes and dextrose are completely reabsorbed or metabolized; water is excreted renally). Biliary/fecal: 0%.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution